News
- Author:
- Mary Jo Dales
Publish date: July 28, 2016
Key clinical point: CAR T-cell therapy may be an option for chronic lymphocytic leukemia patients with residual disease after upfront therapy.
Maj...
News
- Author:
- Mary Jo Dales
Publish date: July 19, 2016
News
- Author:
- Mary Jo Dales
Publish date: July 13, 2016
Key clinical point: Progression-free survival was improved for poor prognosis patients with relapsed chronic lymphocytic leukemia when idelalisib ...
News
- Author:
- Mary Jo Dales
Publish date: July 8, 2016
Key clinical point: Treatment-free remission attempts are safe and are achievable in most patients with chronic myeloid leukemia in chronic phase....
News
- Author:
- Mary Jo Dales
Publish date: July 8, 2016
Key clinical point: The prevalence of smoldering multiple myeloma varied among various socio- and geodemographic subgroups, but overall survival d...
News
- Author:
- Mary Jo Dales
Publish date: July 8, 2016
Key clinical point: In patients with acquired autoimmune thrombotic thrombocytopenic purpura, elevated plasma levels of human neutrophil proteins ...
News
- Author:
- Mary Jo Dales
Publish date: July 8, 2016
Key clinical point: Dematin is newly recognized as a protein crucial to the integrity of red blood cell membranes.
Major finding: Dematin’s ...
News
- Author:
- Mary Jo Dales
Publish date: June 28, 2016
Key clinical point: Obinutuzumab is an option when patients with indolent non-Hodgkin lymphoma relapse or don’t achieve adequate disease con...
News
- Author:
- Mary Jo Dales
Publish date: June 23, 2016
Key clinical point: Acalabrutinib, which has shown efficacy in relapsed CLL, has now shown efficacy as a monotherapy for patients with previously ...
News
- Author:
- Mary Jo Dales
Publish date: June 22, 2016
Key clinical point: Ibrutinib given at doses lower than the standard dose of 420 mg/day may achieve comparable overall survival and progression-fr...
News
- Author:
- Mary Jo Dales
Publish date: June 10, 2016
Key clinical point: The anti-CCR4 monoclonal antibody mogamulizumab was superior to other investigator-selected therapies for the treatment of pat...
News
- Author:
- Mary Jo Dales
Publish date: June 10, 2016
Key clinical point: Adding the monoclonal anti-CD52 antibody alemtuzumab to CHOP (A-CHOP) increased response rates in elderly patients with periph...
News
- Author:
- Mary Jo Dales
Publish date: June 9, 2016
Key clinical point: Non-neutralizing, factor VIII–specific IgG antibodies can contribute significantly to reductions in factor VIII half-lif...
News
- Author:
- Mary Jo Dales
Publish date: June 8, 2016
Key clinical point: Progression-free survival, but not overall survival, was improved after 2 years of maintenance immunotherapy with rituximab.
M...
News
- Author:
- Mary Jo Dales
Publish date: June 6, 2016
Key clinical point: Brentuximab vedotin appears to eradicate residual disease after induction chemotherapy in a small study of patients with limit...
